Study Title
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma
Purpose
To compare the efficacy of TACE with Duravalumab + Bevacizumab, TACE with Duravalumab alone and TACE only.
Eligibility
Study Process
Trial Details
Investigator:
IRB:
WIRB
IRB Number:
Trial Type:
NA
Sponsor:
Astra Zenca
Contact Information:
Hematology Oncology Associates